By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and Braveheart Bio announced positive results from a multi-center, randomized, double-blind, placebo-controlled Phase 2 study evaluating HRS-1893 (BHB-1893), an investigational next-generation cardiac myosin inhibitor (CMI), in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial demonstrated improvements across cardiac biomarkers, echocardiographic measures, and patient-reported outcomes with favorable tolerability.
Clinical Trial Results
| Item | Detail |
|---|---|
| Study Design | Multi-center, randomized, double-blind, placebo-controlled Phase 2 |
| ClinicalTrials.gov ID | NCT06816251 |
| Patient Population | 84 adults with symptomatic nHCM |
| Primary Endpoints | Biomarkers of cardiac wall stress and tissue injury |
| Secondary Endpoints | Diastolic function, cardiac structure, symptoms, exercise capacity |
| Safety Profile | Favorable tolerability with minimal impact on left ventricular ejection fraction (LVEF) |
Product Profile & Innovation
- Molecule Type: Next-generation oral small-molecule cardiac myosin inhibitor (CMI)
- Key Differentiators:
- Rapid onset of action
- Minimal impact on LVEF (addressing safety concerns of first-gen CMIs)
- Ease of use through oral administration
- Therapeutic Rationale: First targeted therapy specifically for non-obstructive HCM, which represents ~30% of all HCM cases
- Development Stage: Phase 2 completed; Phase 3 planning underway
- Market Opportunity: Estimated 200,000+ nHCM patients in major markets with no approved disease-modifying therapies
Partnership Structure
| Aspect | Details |
|---|---|
| License Agreement | September 2025 exclusive worldwide license |
| Hengrui Territory | China (Mainland, Hong Kong SAR, Macao SAR, Taiwan) |
| Braveheart Territory | Worldwide excluding China |
| Rights Coverage | Development, manufacture, and commercialization |
| Strategic Rationale | Combines Hengrui’s development capabilities with Braveheart’s cardiovascular expertise |
The partnership exemplifies the growing trend of Chinese biopharma companies retaining domestic rights while partnering international territories for specialized therapeutic areas.
Market Impact & Outlook
- HCM Therapeutic Gap | Non-obstructive HCM has been historically underserved due to lack of targeted therapies
- Competitive Landscape | First-generation CMIs (mavacamten) approved only for obstructive HCM; HRS-1893 addresses unmet need in nHCM
- Regulatory Pathway | Potential for accelerated approval based on comprehensive biomarker and functional improvements
- Commercial Potential | Peak sales projection of $500–800 million globally if approved across all HCM subtypes
- Investment Implications | Validates Hengrui’s strategy of developing innovative cardiovascular assets beyond oncology
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, partnership arrangements, and commercial expectations for HRS-1893. Actual results may differ due to risks including Phase 3 trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech